On June 11, 2025, RBC Capital reaffirmed its "Outperform" rating for Insmed (INSM, Financial), signalling continued confidence in the company’s performance prospects. Led by analyst Leonid Timashev, this decision reflects a positive outlook amid recent developments within the company.
RBC Capital has also raised the price target for Insmed (INSM, Financial) to $106.00 USD from a previous target of $99.00 USD. This adjustment represents a 7.07% increase, suggesting enhanced investor expectations for the stock's future performance.
The assessment by RBC Capital positions Insmed (INSM, Financial) favorably in the market, aligning with the current "Outperform" rating it has consistently held. This consistent rating indicates that the firm anticipates the stock will surpass average market returns in the coming months.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Insmed Inc (INSM, Financial) is $107.36 with a high estimate of $125.00 and a low estimate of $80.00. The average target implies an upside of 10.62% from the current price of $97.05. More detailed estimate data can be found on the Insmed Inc (INSM) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Insmed Inc's (INSM, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Insmed Inc (INSM, Financial) in one year is $51.35, suggesting a downside of 47.09% from the current price of $97.05. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Insmed Inc (INSM) Summary page.
